Cefazolin

Paul G. Auwaerter, M.D., Edina Avdic, Pharm.D.
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Respiratory tract infections
    • Due to S. pneumoniae, S. aureus (MSSA) and S. pyogenes
  • Urinary tract infections
    • Due to E. coli, P. mirabilis
  • Prostatitis and epididymitis
    • Due to E. coli, PP. mirabilis
  • Skin and skin structure infections
    • Due to S. aureus (MSSA), S. pyogenes, and other strains of streptococci
  • Biliary tract infections
    • Due to E. coli, various strains of streptococci, P. mirabilis, and S. aureus (MSSA)
  • Bone and joint infections due to S. aureus (MSSA)
  • Septicemia
    • Due to S. pneumoniae, S. aureus (MSSA), P. mirabilis, E. coli
  • Endocarditis
    • Due to S. aureus (MSSA) and S. pyogenes
  • Perioperative prophylaxis

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Parotitis (MSSA)
  • Other Staphylococcus aureus (MSSA) infections
  • Other Streptococcus pyogenes (Group A) infections

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2023 Unbound Medicine, Inc. All rights reserved